Novo Nordisk A/S

The bank doubts that the active ingredient in Ozempic and Wegovy will prove effective in fighting Alzheimer's disease

Morgan Stanley gave one of the worst forecasts for Novo. What could bring down the stock?

Telomir Pharmaceuticals, Inc.

Zacks says take a look at the stock ahead of human trials of Telomir's primary drug early next year



Zacks reiterates recommendation on anti-aging drugmaker Telomir despite 47% YTD loss

Sanofi

Eli Lilly and Company

Shares of Vigil Neuroscience, a small drugmaker specializing in rare and common neurodegenerative diseases, <a href="https://finance.yahoo.com/quote/VIGL/">skyrocketed</a> over 240% yesterday, May 22, on <a href="https://investors.vigilneuro.com/news-releases/news-release-details/vigil-neuroscience-enters-definitive-merger-agreement-be">news</a> that pharmagiant Sanofi would acquire the company. This marks Sanofi’s entry into the race to develop an Alzheimer’s treatment, which, <a href="https://oninvest.com/article/pat-small-cap-kompanij-sposobnyh-zarabotat-na-terapii-bolezni-al-cgejmera">according</a> to Bloomberg, might turn into the next obesity market.

Biotech small cap Vigil soars 240% on news of acquisition by pharma giant Sanofi 


Longeveron Inc.

Zacks Small-Cap Research (Zacks SCR) <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_03202025_LGVN_Sorensen.pdf">believes</a> that Longeveron, a micro-cap developer of cellular therapies for aging-related diseases, is worth more than five times its current share price. Its outlook has been bolstered after U.S. authorities gave the <a href="https://scr.zacks.com/news/news-details/2025/LGVN-Announces-Positive-Alzheimers-News/default.aspx">green light</a> to trials of the company’s Alzheimer’s drug and granted it a special designation. Overall, Alzheimer’s drugs are <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">seen</a> as a highly promising niche for investors.